Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9048, USA.
J Virol. 2011 Oct;85(19):9778-88. doi: 10.1128/JVI.00355-11. Epub 2011 Jul 27.
The propensity of RNA viruses to revert attenuating mutations contributes to disease and complicates vaccine development. Despite the presence of virulent revertant viruses in some live-attenuated vaccines, disease from vaccination is rare. This suggests that in mixed viral populations, attenuated viruses may limit the pathogenesis of virulent viruses, thus establishing a virulence threshold. Here we examined virulence thresholds using mixtures of virulent and attenuated viruses in a transgenic mouse model of poliovirus infection. We determined that a 1,000-fold excess of the attenuated Sabin strain of poliovirus was protective against disease induced by the virulent Mahoney strain. Protection was induced locally, and inactivated virus conferred protection. Treatment with a poliovirus receptor-blocking antibody phenocopied the protective effect of inactivated viruses in vitro and in vivo, suggesting that one mechanism controlling virulence thresholds may be competition for a viral receptor. Additionally, the type I interferon response reduces poliovirus pathogenesis; therefore, we examined virulence thresholds in mice lacking the alpha/beta interferon receptor. We found that the attenuated virus was virulent in immunodeficient mice due to the enhanced replication and reversion of attenuating mutations. Therefore, while the type I interferon response limits the virulence of the attenuated strain by reducing replication, protection from disease conferred by the attenuated strain in immunocompetent mice can occur independently of replication. Our results identified mechanisms controlling the virulence of mixed viral populations and indicate that live-attenuated vaccines containing virulent virus may be safe, as long as virulent viruses are present at levels below a critical threshold.
RNA 病毒倾向于回复减毒突变,这导致了疾病的发生,并使疫苗的开发复杂化。尽管一些减毒活疫苗中存在毒力回复的病毒,但接种疫苗后发病的情况很少见。这表明,在混合病毒群体中,减毒病毒可能会限制毒力病毒的发病机制,从而建立一个毒力阈值。在这里,我们使用脊髓灰质炎病毒感染的转基因小鼠模型研究了毒力阈值。我们发现,在含有减毒的 Sabin 株脊髓灰质炎病毒的 1000 倍过量时,可预防由毒力 Mahoney 株引起的疾病。这种保护是局部诱导的,并且失活病毒可提供保护。体外和体内实验表明,使用脊髓灰质炎病毒受体阻断抗体治疗可模拟失活病毒的保护作用,这表明控制毒力阈值的一种机制可能是对病毒受体的竞争。此外,I 型干扰素反应可降低脊髓灰质炎病毒的发病机制;因此,我们在缺乏α/β干扰素受体的小鼠中检查了毒力阈值。我们发现,在免疫缺陷小鼠中,由于减毒突变的增强复制和回复,减毒病毒变得具有毒力。因此,尽管 I 型干扰素反应通过减少复制来限制减毒株的毒力,但在免疫功能正常的小鼠中,减毒株所赋予的疾病保护作用可能独立于复制而发生。我们的结果确定了控制混合病毒群体毒力的机制,并表明含有毒力病毒的活减毒疫苗可能是安全的,只要毒力病毒的存在水平低于临界阈值。